Role of hypoxia-inducible factor – 1 alpha on the progression of cervical intraepithelial neoplasia and cervical cancer: a narrative review
Open Access
- 10 September 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1922814
Abstract
Cervical cancer represents a global public health problem, hence the importance of optimizing therapeutic options and expanding knowledge of prognostic markers. Clinical and experimental evidence shows that hypoxia-inducible factor (HIF) is a key inducer of aggressive phenotypes in cervical cancer: promoting angiogenesis, invasion, epithelial-mesenchymal transition (EMT), modulation of the immune microenvironment, and contributing to resistance to radiotherapy/chemotherapy in a possible synergistic effect with the human papilloma virus oncogenes. Hypoxic microenvironments that modulate the early activation of HIF pathways may be present in pre-invasive lesions and favor the acquisition of invasive phenotypes that precede invasion. This review highlights the mechanisms of HIF-1α in the progression of cervical intraepithelial neoplasia and cervical cancer. In this regard, HIF-1α is involved in the expression of genes related to angiogenesis, apoptosis and progression such as GLUT1, uPAR, BIRC5, EPO, EpoR, LIMD1, VHL, MET and pro-angiogenic genes (VEGF, PGF, PDGF-β, PAI-1, MMP-2, MMP-9, ANG-1, ANG-2, using pathways such as YAP/TA2. However, the balance between antitumor factors (miR-143) and protumor factors can define the progression of this neoplasia. In the future, the characterization of hypoxia signatures and the evaluation of HIF-1α pathway inhibitors are promising tools for optimizing outcomes in the treatment of cervical cancer, integrated with modern, high-precision radiation therapy techniques and predictive models based on imaging and artificial intelligence, which represent a key pillar of personalized oncology in cervical cancer, with the potential to improve tumor control and reduce toxicity; however, specific clinical trials are still needed to validate their impact on survival and safety.Keywords
This publication has 179 references indexed in Scilit:
- HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospectsCellular and Molecular Life Sciences, 2025
- Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical CancerJAMA Oncology, 2024
- The impact of cycling hypoxia on the phenotype of HPV‐positive cervical cancer cellsJournal of Medical Virology, 2023
- The multifaceted role of reactive oxygen species in tumorigenesisCellular and Molecular Life Sciences, 2020
- Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based researchThe Journal of Pathology, 2020
- The role of the hypoxia‐Nrp‐1 axis in the activation of M2‐like tumor‐associated macrophages in the tumor microenvironment of cervical cancerMolecular Carcinogenesis, 2018
- MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkersJournal of Cellular Biochemistry, 2018
- Increased vascular endothelial growth factor expression, CD3‐positive cell infiltration, and oxidative stress in premalignant lesions of the cervixCancer, 2009
- The role of hypoxia-inducible factors in cancerCellular and Molecular Life Sciences, 2007
- Mitochondrial Reactive Oxygen Species are Required for Hypoxic HIFα Stabilization2006